Patient characteristics at the time of FDG/PET and tissue biopsy (n = 332)
. | CLL histology . | . | |||||
---|---|---|---|---|---|---|---|
Characteristic . | HIC (n = 120) . | HAC (n = 117) . | RS (n = 95) . | P value . | |||
No. . | % . | No. . | % . | No. . | % . | ||
Age, y | |||||||
Median | 60 | 62 | 63 | .18 | |||
Range | 34-83 | 31-85 | 41-82 | ||||
Male | 76 | 64 | 81 | 70 | 61 | 66 | .61 |
No. of prior treatments | |||||||
Median | 0 | 2 | 2 | <.0001 | |||
Range | 0-9 | 0-13 | 0-8 | ||||
Prior SCT | 7 | 6 | 14 | 12 | 15 | 16 | .06 |
Refractory to last therapy* | 24/46 | 52 | 49/100 | 49 | 47/84 | 56 | .56 |
Constitutional symptoms | 0 | 0 | 29 | 25 | 55 | 59 | <.0001 |
PS 2-4 | 1 | 1 | 19 | 16 | 21 | 23 | <.0001 |
Bulky disease† | 23 | 19 | 37 | 32 | 22 | 24 | .08 |
WBC ×109/L | |||||||
Median | 9.1 | 7.9 | 5.9 | .0009 | |||
Range | 2.1-362.6 | 0.8-292.8 | 0.1-127.2 | ||||
Hemoglobin, g/dL | |||||||
Median | 13.3 | 11.7 | 11 | <.0001 | |||
Range | 4.6-16.5 | 7.7-16.1 | 2.8-16.4 | ||||
Platelets ×109/L | |||||||
Median | 187 | 121 | 120 | <.0001 | |||
Range | 10-382 | 11-494 | 3-593 | ||||
LDH, UI/L | |||||||
Median | 540 | 752 | 757 | <.0001 | |||
Range | 332-1 681 | 304-4 225 | 253-14 185 | ||||
Beta2-microglobulin, mg/L | |||||||
Median | 2.9 | 5 | 4.7 | <.0001 | |||
Range | 1.4-15.8 | 1.6-16.8 | 1.6-18 | ||||
CD38 positivity | 62/106 | 58 | 73/107 | 68 | 53/75 | 71 | .17 |
ZAP70 expression | 51/74 | 69 | 69/81 | 85 | 33/49 | 67 | .02 |
Del17p | 12/67 | 18 | 28/83 | 34 | 12/59 | 20 | .053 |
Time from diagnosis to FDG/PET, mo | |||||||
Median | 4 | 57 | 71 | <.0001 | |||
Range | 0-300 | 0-235 | 0-402 |
. | CLL histology . | . | |||||
---|---|---|---|---|---|---|---|
Characteristic . | HIC (n = 120) . | HAC (n = 117) . | RS (n = 95) . | P value . | |||
No. . | % . | No. . | % . | No. . | % . | ||
Age, y | |||||||
Median | 60 | 62 | 63 | .18 | |||
Range | 34-83 | 31-85 | 41-82 | ||||
Male | 76 | 64 | 81 | 70 | 61 | 66 | .61 |
No. of prior treatments | |||||||
Median | 0 | 2 | 2 | <.0001 | |||
Range | 0-9 | 0-13 | 0-8 | ||||
Prior SCT | 7 | 6 | 14 | 12 | 15 | 16 | .06 |
Refractory to last therapy* | 24/46 | 52 | 49/100 | 49 | 47/84 | 56 | .56 |
Constitutional symptoms | 0 | 0 | 29 | 25 | 55 | 59 | <.0001 |
PS 2-4 | 1 | 1 | 19 | 16 | 21 | 23 | <.0001 |
Bulky disease† | 23 | 19 | 37 | 32 | 22 | 24 | .08 |
WBC ×109/L | |||||||
Median | 9.1 | 7.9 | 5.9 | .0009 | |||
Range | 2.1-362.6 | 0.8-292.8 | 0.1-127.2 | ||||
Hemoglobin, g/dL | |||||||
Median | 13.3 | 11.7 | 11 | <.0001 | |||
Range | 4.6-16.5 | 7.7-16.1 | 2.8-16.4 | ||||
Platelets ×109/L | |||||||
Median | 187 | 121 | 120 | <.0001 | |||
Range | 10-382 | 11-494 | 3-593 | ||||
LDH, UI/L | |||||||
Median | 540 | 752 | 757 | <.0001 | |||
Range | 332-1 681 | 304-4 225 | 253-14 185 | ||||
Beta2-microglobulin, mg/L | |||||||
Median | 2.9 | 5 | 4.7 | <.0001 | |||
Range | 1.4-15.8 | 1.6-16.8 | 1.6-18 | ||||
CD38 positivity | 62/106 | 58 | 73/107 | 68 | 53/75 | 71 | .17 |
ZAP70 expression | 51/74 | 69 | 69/81 | 85 | 33/49 | 67 | .02 |
Del17p | 12/67 | 18 | 28/83 | 34 | 12/59 | 20 | .053 |
Time from diagnosis to FDG/PET, mo | |||||||
Median | 4 | 57 | 71 | <.0001 | |||
Range | 0-300 | 0-235 | 0-402 |